Number 904 • October 2020

# Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)

Due to the shortages of the following products, GLN-Olmesartan 20 mg Tablet (DIN 02469812) manufactured by Glenmark Pharmaceuticals Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description	Manufacturer
02456311	ACH-Olmesartan 20 mg Tablet	Accord Healthcare Inc
02442191	Act Olmesartan 20 mg Tablet	Actavis Pharma Company
02453452	Apo-Olmesartan 20 mg Tablet	Apotex Inc.
02443864	Auro-Olmesartan 20 mg Tablet	Auro Pharma Inc.
02461641	Jamp-Olmesartan 20 mg Tablet	Jamp Pharma Corporation
02461307	pms-Olmesartan 20 mg Tablet	Pharmascience Inc.
02443414	Sandoz Olmesartan 20 mg Tablet	Sandoz Canada Inc.
02318660	Olmetec 20 mg Tablet	Merck Canada Inc.

Accord Healthcare Inc., Apotex Inc., and Merck Canada Inc. have advised Alberta Blue Cross that the shortages of ACH-Olmesartan 20 mg Tablet (DIN 02456311), Apo-Olmesartan 20 mg Tablet (DIN 02453452), and Olmetec 20 mg Tablet (DIN 02318660), respectively, have been resolved.

As a result, GLN-Olmesartan 20 mg Tablet (DIN 02469812) will no longer be considered a temporary benefit for the *ADBL* after **November 2, 2020**. These products were removed from the Critical Supply Product List **October 2, 2020**.

Due to the shortages of the following products, GLN-Olmesartan 40 mg Tablet (DIN 02469820) manufactured by Glenmark Pharmaceuticals Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description	Manufacturer	
02456338	ACH-Olmesartan 40 mg Tablet	Accord Healthcare Inc	
02442205	Act Olmesartan 40 mg Tablet	Actavis Pharma Company	
02453460	Apo-Olmesartan 40 mg Tablet	Apotex Inc.	
02443872	Auro-Olmesartan 40 mg Tablet	Auro Pharma Inc.	
02461668	Jamp-Olmesartan 40 mg Tablet	Jamp Pharma Corporation	
02461315	pms-Olmesartan 40 mg Tablet	Pharmascience Inc.	
02443422	Sandoz Olmesartan 40 mg Tablet	Sandoz Canada Inc.	
02318679	Olmetec 40 mg Tablet	Merck Canada Inc.	

Accord Healthcare Inc., Apotex Inc., Jamp Pharma Corporation, Sandoz Canada Inc. and Merck Canada Inc. have advised Alberta Blue Cross that the shortages of ACH-Olmesartan 40 mg Tablet (DIN 02456338), Apo-Olmesartan 40 mg Tablet (DIN 02453460), Jamp-Olmesartan 40 mg Tablet (DIN 02461668) and Olmetec 40 mg Tablet (DIN 02318679), respectively, have been resolved.

As a result, GLN-Olmesartan 40 mg Tablet (DIN 02469820) will no longer be considered a temporary benefit for the *ADBL* after **November 2, 2020**. These products were removed from the Critical Supply Product List **October 2, 2020**.

Due to the shortages of Adalat XL 60 mg Extended-Release Tablet (DIN 02155990) manufactured by Bayer Inc. and Mylan-Nifedipine ER 60 mg Extended-Release Tablet (DIN 02321149) manufactured by Mylan Pharmaceuticals ULC, pms-Nifedipine ER 60 mg Extended-Release Tablet (DIN 02416301) was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Mylan Pharmaceuticals ULC has advised Alberta Blue Cross that the shortage of Mylan-Nifedipine ER 60 mg Extended-Release Tablet (DIN 02321149) has been resolved.

As a result, pms-Nifedipine ER 60 mg Extended-Release Tablet (DIN 02416301) will no longer be considered a temporary benefit for the ADBL after **November 2, 2020**. These products were removed from the Critical Supply Product List **October 2, 2020**.

## Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Pinaverium 50 mg Tablet (DIN 02469677) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **November 2, 2020**. The following grouping was removed from the Critical Supply Product List **September 30, 2020**.

#### **PINAVERIUM BROMIDE**

### **50 MG TABLET**

00002469677	APO-PINAVERIUM	APX	\$ 0.3066
00001950592	DICETEL	BGP	\$ 0.3709

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php** 



